Actively Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors
Led by Bristol-Myers Squibb · Updated on 2026-01-05
32
Participants Needed
12
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986504 in participants with advanced solid tumors.
CONDITIONS
Official Title
A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed solid tumor with homozygous MTAP gene deletion detected in tumor tissue
- Unresectable or metastatic disease not suitable for curative therapies after progression on prior treatments
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- At least one measurable tumor lesion per RECIST 1.1 at baseline
You will not qualify if you...
- Prior treatment with Protein arginine methyltransferase 5 (PRMT5) or Methionine adenosyltransferase 2A (MAT2A) inhibitors
- Active brain metastases or carcinomatous meningitis
- History of gastrointestinal disease or conditions likely to affect absorption of study treatment or ability to swallow oral medications
- Known severe hypersensitivity to study treatment or its excipients
- Other protocol-defined inclusion/exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Beijing Cancer hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
2
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Actively Recruiting
3
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510120
Actively Recruiting
4
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China, 518036
Actively Recruiting
5
Local Institution - 0006
Harbin, Heilongjiang, China, 150081
Not Yet Recruiting
6
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China, 453100
Actively Recruiting
7
Shandong Cancer Hospital
Jinan, Shandong, China, 250117
Actively Recruiting
8
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
9
Kanagawa cancer center
Yokohama, Kanagawa, Japan, 2418515
Actively Recruiting
10
Shizuoka Cancer Center
Sunto-gun, Shizuoka, Japan, 411-8777
Actively Recruiting
11
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan, 104-0045
Actively Recruiting
12
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan, 135-8550
Actively Recruiting
Research Team
B
BMS Study Connect Contact Center, www.BMSStudyConnect.com
CONTACT
F
First line of the email MUST contain the NCT# and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here